Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9P2J5
UPID:
SYLC_HUMAN
Alternative names:
Leucyl-tRNA synthetase
Alternative UPACC:
Q9P2J5; A2RRR4; A7E266; B4DJ10; Q2TU79; Q9NSE1
Background:
Leucine--tRNA ligase, also known as Leucyl-tRNA synthetase, plays a pivotal role in protein synthesis. It catalyzes the attachment of leucine to its cognate tRNA, a critical step for accurate translation and protein production. This enzyme ensures the fidelity of the amino acid incorporation into proteins, showcasing a remarkable ability to correct mistakes by hydrolyzing mischarged tRNAs.
Therapeutic significance:
Leucine--tRNA ligase's malfunction is linked to Infantile liver failure syndrome 1, a severe condition marked by acute liver failure early in life. This association highlights the enzyme's essential role beyond protein synthesis, implicating it in liver health and development. Targeting this enzyme could offer novel therapeutic avenues for treating liver-related disorders.